Pharmaceuticals News and Research

RSS

Analysis explores the importance of CNS-related conditions and their impact on epilepsy management

Depression, anxiety disorder, bipolar disorder, Attention Deficit Hyperactivity Disorder (ADHD), sleep disorder and migraine: These are among the comorbidities reported to occur more often in people who said they had been diagnosed with epilepsy versus those without an epilepsy diagnosis, according to a survey of approximately 173,000 households across the U.S.

4 Dec 2009

New discoveries to treat life-threatening blood disorder presented at ASH annual meeting

A genetic variation that may indicate a patient's risk of developing a potentially life-threatening blood disorder if exposed to certain pharmaceutical therapies or chemicals is one of several medical discoveries scientists at cancer diagnostics leader Quest Diagnostics will present during the 51st American Society of Hematology (ASH) Annual Meeting and Exposition, December 5-8, 2009, in New Orleans, LA.

4 Dec 2009

Internap Network Services completes SAS 70 Type II audit for its company-controlled data centers

Internap Network Services Corporation, a global provider of end-to-end Internet business solutions, today announced it has successfully completed the Statement on Auditing Standards No. 70 (SAS 70) Type II audit for its company-controlled data centers. This activity is part of a continued commitment by Internap to provide advanced services to IT professionals interested in facilities that have demonstrated capabilities against the highest standards for service delivery.

4 Dec 2009

Amgen/GSK's Prolia will be preferred as second- or third-line therapy for osteoporosis

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the majority of surveyed clinicians say they will use Amgen/GlaxoSmithKline's Prolia as either a second- or third-line therapy for osteoporosis if the drug receives regulatory approval for the indication.

4 Dec 2009

APCER Pharma Solutions' webinar on 2010 FDA drug safety and pharmacovigilance initiatives

APCER Pharma Solutions, Inc.’s webinar on 2010 FDA drug safety and pharmacovigilance initiatives gave more than 250 professionals in the life sciences-related industries the jump start they needed to prepare for important changes next year.

4 Dec 2009

New SPC3649 drug found effective in treating HCV infections

In a dramatic finding, a new drug for hepatitis C virus (HCV) infections that targets liver cells produced a substantial drop in blood levels of the virus in animals and continued to work up to several months after treatment, say scientists at the Southwest Foundation for Biomedical Research (SFBR) in San Antonio.

4 Dec 2009

PPA provides 'hopeful news' for patients struggling financially about paying for their medicines

The Redwood Gazette recently reported that there is "hopeful news" for patients who are struggling financially and worried about paying for their medicines. The Partnership for Prescription Assistance (PPA) has helped more than 6 million patients find programs providing prescription medicines for free or nearly free.

4 Dec 2009

Santaris Pharma's LNA technology based microRNA-targeted therapy holds promise for HCV

A study published online in this week's Science shows that SPC3649, a breakthrough microRNA-targeted therapy developed by Santaris Pharma A/S using its proprietary Locked Nucleic Acid (LNA) technology, holds promise as a novel treatment for patients infected with the Hepatitis C virus (HCV).

4 Dec 2009

Integrative medicine and treatment strategies for the H1N1 infection discussed at the Buchang Forum

According to the World Health Organization, the human H1N1/09 Type A influenza ("Swine Flu") has reached a pandemic level. Over 500,000 cases have been confirmed worldwide with at least 6,500 fatalities. Since there is no longer a requirement to test and report individual cases, these numbers undoubtedly understate the real situation.

4 Dec 2009

Kyto advancing with a program for humanization of the mAbTCR23 antibody

Kyto Biopharma Inc., is a biotechnology company focused on developing monoclonal antibody and oligonucleotide targeting therapeutics based on a proprietary vitamin B12 platform for the treatment of various forms of cancer.

4 Dec 2009

Pfizer announces a $9M cancer research collaboration in British Columbia

Pfizer is entering into a three-year, $9-million research collaboration with the BC Cancer Agency and the Vancouver Prostate Centre, a University of British Columbia (UBC) and Vancouver General Hospital (VGH) Centre of Excellence, to tackle new treatment avenues for breast, ovarian and prostate cancer. This is the single-largest investment by Pfizer into British Columbia's public research sector, and it recognizes the strength and world-class cancer expertise that resides in this province.

4 Dec 2009

KFDA approves RPC's Onko-Sure in Vitro Diagnostic cancer test

US-based pharmaceutical company Radient Pharmaceuticals Corporation (RPC) announced today the Korean Food & Drug Administration (KFDA) has approved RPC's Onko-Sure™ in Vitro Diagnostic cancer test for routine clinical testing and government reimbursement throughout Korea.

4 Dec 2009

ISIS-FXIRx and ISIS-SMNRx included in Isis Pharmaceuticals' development pipeline

Isis Pharmaceuticals, Inc. announced today that it has added two new drugs to its development pipeline, ISIS-FXIRx and ISIS-SMNRx.

4 Dec 2009

Two antimicrobial drug developing companies evaluate new approach for treating bacterial infections

Chaperone Technologies, Inc. and MerLion Pharmaceuticals Pte Ltd., both privately-held companies developing new antimicrobial drugs, announced today that they are together evaluating a unique approach for the treatment of resistant and life-threatening bacterial infections.

4 Dec 2009

Data from recent clinical trial for Caldolor Injection to be presented

Cumberland Pharmaceuticals Inc. announced today that data from a recent clinical trial for Caldolor® (ibuprofen) Injection, an intravenous treatment for pain and fever, will be presented at the 44th American Society of Health-System Pharmacists (ASHP) Midyear Clinical Meeting in Las Vegas, Nevada, in December.

4 Dec 2009

ISTODAX included in the updated NCCN Clinical Practice Guidelines in Oncology

Gloucester Pharmaceuticals announced today that ISTODAX® (romidepsin) has been included in the updated National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology™ as a suggested systemic treatment option for patients with mycosis fungoides and Sézary syndrome—two of the most common types of cutaneous T-cell lymphoma (CTCL).

4 Dec 2009

Patent titled 'System and Method for 4D Reconstruction and Visualization' receives issuance in Japan

VirtualScopics, Inc., a leading provider of quantitative imaging for clinical trials, announced today that its patent titled "System and Method for 4D Reconstruction and Visualization" recently received issuance in Japan.

4 Dec 2009

BioMed Realty Trust receives additional space at Landmark under new lease agreement

BioMed Realty Trust, Inc. announced today that it has entered into a new lease with Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) for approximately 131,000 square feet of additional, newly-constructed laboratory and office space at The Landmark at Eastview campus in Tarrytown, New York.

4 Dec 2009

Update on European commercial launch of MuGard for oral mucositis provided

ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP), today provided an update on its European commercial launch of MuGard, an FDA approved treatment for oral mucositis, a debilitating side effect of radiation treatment and chemotherapy.

4 Dec 2009

Option Six acquired by GP Strategies

GP Strategies Corporation, announced that its principal operating subsidiary, global performance improvement solutions provider General Physics Corporation, has acquired Option Six, Inc., a provider of custom courseware development with expertise in the software and pharmaceutical industries.

4 Dec 2009

Pharmaceuticals News and Research

Analysis explores the importance of CNS-related conditions and their impact on epilepsy management

New discoveries to treat life-threatening blood disorder presented at ASH annual meeting

Internap Network Services completes SAS 70 Type II audit for its company-controlled data centers

Amgen/GSK's Prolia will be preferred as second- or third-line therapy for osteoporosis

APCER Pharma Solutions' webinar on 2010 FDA drug safety and pharmacovigilance initiatives

New SPC3649 drug found effective in treating HCV infections

PPA provides 'hopeful news' for patients struggling financially about paying for their medicines

Santaris Pharma's LNA technology based microRNA-targeted therapy holds promise for HCV

Integrative medicine and treatment strategies for the H1N1 infection discussed at the Buchang Forum

Kyto advancing with a program for humanization of the mAbTCR23 antibody

Pfizer announces a $9M cancer research collaboration in British Columbia

KFDA approves RPC's Onko-Sure in Vitro Diagnostic cancer test

ISIS-FXIRx and ISIS-SMNRx included in Isis Pharmaceuticals' development pipeline

Two antimicrobial drug developing companies evaluate new approach for treating bacterial infections

Data from recent clinical trial for Caldolor Injection to be presented

ISTODAX included in the updated NCCN Clinical Practice Guidelines in Oncology

Patent titled 'System and Method for 4D Reconstruction and Visualization' receives issuance in Japan

BioMed Realty Trust receives additional space at Landmark under new lease agreement

Update on European commercial launch of MuGard for oral mucositis provided

Option Six acquired by GP Strategies

Industry Focus - Biopharma eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Managing vibration in IVF laboratories

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence